跳至主要内容
临床试验/NCT05194371
NCT05194371已完成不适用

Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2021年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
3,000
试验地点
1
主要终点
Overall survival

研究概览

简要总结

In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation, economic burden, and quality of life.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with esophageal cancer who received definitive radiotherapy (radiotherapy dose ≥50Gy) from 2015 to 2016
  • The radiation field included primary esophageal tumor with or without lymph node metastasis

排除标准

  • Radiotherapy dose < 50Gy
  • Palliative radiotherapy
  • The radiation field are metastatic areas, such as bone, brain, adrenal gland, isolated metastatic lymph nodes, etc

结局指标

主要结局

Overall survival

时间窗: 5 year

次要结局

  • the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess quality of life (QOL)(5 year)
  • Proportion of using chemotherapy or target therapy concurrently with radiotherapy(2 month)
  • Costs of treatment(5 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Luhua Wang

Principal Investigator

Chinese Academy of Medical Sciences

研究点 (1)

Loading locations...

相似试验